María Cañibano-Pico

This study develops and evaluates two novel antibodies, 1B12 and 11G2, for more sensitive detection of HTT1a in Huntington's disease mouse models compared to the existing MW8 antibody.

The paper shows that lowering HTT1a transcript levels delays molecular and neuropathological phenotypes in a Huntington's disease mouse model.

This study shows that reducing MSH3 in Huntington's disease mouse models prevents somatic CAG repeat expansion but does not accelerate disease onset, suggesting somatic expansion may not be required for pathogenesis.

The paper shows that mutant HTT levels decrease with CAG repeat expansion, suggesting therapeutic strategies should target HTT1a instead of full-length HTT.